Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
Alzheon has presented new analyses of previous Phase III data for tramiprosate, an investigational amyloid anti-aggregation agent and the active molecule of prodrug ALZ-801, in an oral presentation at the 9th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego. 9 December 2016
US specialty pharma Vanda Pharmaceuticals has come to an agreement with Canadian generics firm Apotex in a patent dispute over the schizophrenia drug Fanapt (iloperidone). 8 December 2016
Kadimastem has signed a memorandum of understanding with South Korean company Corestem, for a broad strategic collaboration between the companies. 8 December 2016
The UK’s Competition and Markets Authority (CMA) today announced that it has fined two compoanies nearly £90 million ($114.4 million) for charging excessive prices to the National Health Service (NHS) for an anti-epilepsy drug. 7 December 2016
Switzerland’s Neurimmune and TVM Capital Life Science have joined forces create and fund a single-asset biotech firm focused on amyotrophic lateral sclerosis (ALS). 7 December 2016
US clinical-stage biotech Sage Therapeutics was trading 7% higher after Tuesday’s trading at $55.68 following news from its development plan for its SAGE-547 program in postpartum depression (PPD). 7 December 2016
The neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%. 7 December 2016
Positive results of a Phase IIa clinical trial FAST (F17464 in Acute Schizophrenia Trial), conducted on the molecule F17464 on patients with an acute episode of schizophrenia were announced today. 6 December 2016
Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders, has been launched. 5 December 2016
Drugs used for type 2 diabetes mellitus could alleviate symptoms among Alzheimer’s disease patients, or even exert potential disease-modifying effects. 2 December 2016
A study that evaluated the use of the neuropathic pain drug Lyrica (pregabalin) as adjunctive therapy for pediatric epilepsy patients four to 16 years of age with partial onset seizures met its primary endpoint. 2 December 2016
Confirmation that Johnson & Johnson is interested in buying the Swiss group Actelion sent the target's shares up as much as 14% Friday morning, but a deal looks unlikely – at least at its current value, according to EP Vantage. 27 November 2016
US clinical-stage neuroscience focussed Cognition Therapeutics has provided its comments and perspective on the disappointing Phase III clinical trial data of Eli Lilly's Alzheimer's disease medicine, solanezumab, which saw more than $10 billion wiped off the pharma major’s market capitalization yesterday. 24 November 2016
In another disappointment for Alzheimer’s sufferers, and notably for US pharma major Eli Lilly, disappointing late-stage study results with its lead drug candidate for the condition have been revealed. 23 November 2016
Ireland-headquartered Allergan has continued expanding its business through strategic takeovers, this time to build on its commitment to Alzheimer’s disease, making this the ninth such deal this year. 23 November 2016
US drug developer Acorda Therapeutics watched its shares slide as much as 13% yesterday, having fallen by over 50% year-to-date, after it revealed another clinical development disappointment, this time with its stroke drug candidate. 22 November 2016
US biotech firm Celgene, through an affiliate, has acquired assets related to the proteasome inhibitor, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma. 22 November 2016
Positive top-line results for erenumab from a global Phase III, randomized, double-blind, placebo-controlled STudy to evaluate the efficacy and safety of erenumab in migRaIne preVEntion (STRIVE) have been released. 18 November 2016
The US Food and Drug Administration has granted Fast Track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609. 18 November 2016